Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Azzak34on Dec 14, 2023 5:04pm
127 Views
Post# 35785555

RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre BizzariOur company is testing a reovirus. Only 1 oncolytic reovirus has ever been approved to fight cancer in 1 indication, melanoma. We are building our case to be the 2nd in at least 2 indications. Results have been great, missteps have been made but the trajectory, over time, has been forward. Mistakes in R&D in any industry are not corrected quickly, never mind years long studies and extensive regulatory input in the medical field. Maybe we need a switch up on the board, maybe we should ask for accountability for past failures, maybe you guys write the company and make your case rather than whinge on here everyday. 

Science takes a long time. Especially when you're trying to produce a product that isn't widely used in fighting cancer, but is producing strong efficacious results. 

Our board and Advisors are beasts. They're not attaching their name to a failing, untruthful or unscrupulous company. It makes zero sense for them to be attached to us for any other reason than we're getting Pela to market. 

It's your impatience that is the problem. We're getting there, slowly but surely and this guys addition to the ranks "affirms" that!!!! 
<< Previous
Bullboard Posts
Next >>